📋 Tender Overview
bioLytical Laboratories Inc. bioLytical a global leader in rapid in vitro medical diagnostics announced it received CE Mark for the worlds first one minute HCV Antibody Test allowing it to sell its kits across Europe. The innovative rapid through-flow technology allows INSTI to provide accurate test results in real-time offering medical professionals the ability to test patients easily and flexibly in different locations. Affecting an estimated 71 million globally Hepatitis C HCV is a growing international health concern. It can remain asymptomatic and thus undiagnosed and if left untreated can cause serious health problems including liver damage cirrhosis liver cancer and even death. With both taking the test and receiving results in real-time bioLyticals INSTI HCV Antibody Test will help connect more people to care. Treatment can cure more than 95 of people with Hepatitis C but access to diagnosis is still too low. Ending an epidemic starts with testing. Thats why weve developed an all-new one minute solution for HCV antibody testing. By using our proven INSTI platform we were able to take advantage of our rapid test technology to develop a fast and easy-to-use test with over 99 accuracy said Robert Mackie CEO for bioLytical. Ending HCV in Europe begins with testing. By providing access to the worlds first one minute HCV test we are excited to play a role in reducing transmission in Europe to help diagnose and connect individuals to care. Leveraging bioLyticals proven INSTI technology the INSTI HCV Antibody Test was designed to identify HCV antibodies paving the way for reliable and fast screening using a simple fingerstick method to receive results that are more than 99 percent accurate in only one minute. bioLytical will manufacture the INSTI HCV Antibody Tests in its facility in Richmond British Columbia to sell and distribute across Europe. Proven Testing Technology Now Broadly Available The INSTI HCV Antibody Test uses the same proven and innovative technology as the existing INSTI platform joining the INSTI line-up of infectious through-flow rapid tests that have been available for sale in Europe since 2015 including the HIV-1HIV-2 Antibody Test the HIV Self Test the Multiplex HIV Syphilis Ab Test and the COVID-19 Antibody Test.
